Association of survival and hyperthermia after rt-PA for ischemic stroke

Acta Neurol Scand. 2018 Dec;138(6):574-578. doi: 10.1111/ane.13011. Epub 2018 Aug 29.

Abstract

Background: Hyperthermia in patients with acute ischemic stroke is associated with poor outcome. Although previous studies have shown a negative effect on functional outcome, even in patients treated with intravenous recombinant tissue plasminogen activator (rt-PA), the effect on survival remains unclear.

Aims of the study: The aim of this study was to evaluate the association between the functional and survival prognosis and hyperthermia in patients with acute ischemic stroke treated with rt-PA.

Methods: We studied 120 patients treated with rt-PA from 2306 consecutive Japanese patients with acute cerebral infarction at Aomori Prefectural Central Hospital between December 2009 and March 2017. We defined hyperthermia as ≥38°C within 72 hours after rt-PA administration. Propensity score matching was used to compare 34 non-hyperthermia and hyperthermia patient pairs.

Results: Final modified Rankin Scale scores were higher in the hyperthermia group than in the non-hyperthermia group. In addition, the Kaplan-Meier model showed that the non-hyperthermia group had significantly better survival rates than the hyperthermia group (hazard ratio, 5.3; 95% confidence intervals, 1.2-24.8).

Conclusions: Hyperthermia within 3 days after rt-PA is associated with poor functional prognosis and survival outcome in patients with acute cerebral infarction.

Keywords: cerebral infarction; functional prognosis; hyperthermia; ischemic stroke; propensity score analysis; recombinant tissue plasminogen activator; survival prognosis.

MeSH terms

  • Aged
  • Brain Ischemia / complications
  • Brain Ischemia / drug therapy
  • Brain Ischemia / mortality
  • Female
  • Fever / etiology*
  • Fever / mortality
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Risk Factors
  • Stroke / complications*
  • Stroke / drug therapy*
  • Stroke / mortality
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator